Cite
Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis.
MLA
Li, Michael, et al. “Outcomes after Resumption of Immune Checkpoint Inhibitor Therapy after High‐grade Immune‐mediated Hepatitis.” Cancer (0008543X), vol. 126, no. 23, Dec. 2020, pp. 5088–97. EBSCOhost, https://doi.org/10.1002/cncr.33165.
APA
Li, M., Sack, J. S., Rahma, O. E., Hodi, F. S., Zucker, S. D., & Grover, S. (2020). Outcomes after resumption of immune checkpoint inhibitor therapy after high‐grade immune‐mediated hepatitis. Cancer (0008543X), 126(23), 5088–5097. https://doi.org/10.1002/cncr.33165
Chicago
Li, Michael, Jordan S. Sack, Osama E. Rahma, F. Stephen Hodi, Stephen D. Zucker, and Shilpa Grover. 2020. “Outcomes after Resumption of Immune Checkpoint Inhibitor Therapy after High‐grade Immune‐mediated Hepatitis.” Cancer (0008543X) 126 (23): 5088–97. doi:10.1002/cncr.33165.